CMA incorrectly analysed evidence in Prochlorperazine decision, drugmaker says
The UK’s competition watchdog failed to analyse evidence correctly when fining pharmaceutical companies for sharing the market for an anti-nausea drug and “flippantly” accused two of the drugmakers of creating a false paper trail, the Competition Appeal Tribunal has heard.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.